PD-1-CTLA4 bsAbs could become useful in the NSCLC setting because of preferential binding to CTLA-4 on PD-1-activated dual-positive T cells in the tumor (limiting toxicities in normal organs). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.